Mark Lawrence Weber

Title: Mark Lawrence Weber: Innovator in Neurodegenerative Disease Treatment

Introduction

Mark Lawrence Weber is a notable inventor based in Farmington Hills, MI (US). He has made significant contributions to the field of medicine, particularly in the treatment of neurodegenerative diseases. His innovative approach has led to the development of novel methods that utilize known compounds for therapeutic purposes.

Latest Patents

Mark Weber holds a patent for "Methods for treating neurodegenerative diseases and disorders." This invention focuses on the novel uses of N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and their pharmaceutically acceptable acid addition salts. The compounds, such as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride and N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea, are utilized for treating various neurodegenerative disorders, including perinatal asphyxia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. Additionally, the invention explores the novel uses of known anticonvulsant compounds like ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.

Career Highlights

Mark Weber is associated with Warner-Lambert Company, where he has been able to apply his expertise in pharmaceutical innovation. His work has been instrumental in advancing treatment options for patients suffering from debilitating neurodegenerative conditions. With a patent portfolio that includes 1 patent, he continues to contribute to the medical field.

Collaborations

Throughout his career, Mark Weber has collaborated with various professionals, including his coworker Charles Price Taylor, Jr. These collaborations have fostered an environment of innovation and have led to significant advancements in the treatment of neurodegenerative diseases.

Conclusion

Mark Lawrence Weber's contributions to the field of medicine, particularly in neurodegenerative disease treatment, highlight his innovative spirit and dedication to improving patient outcomes. His work continues to inspire future advancements in pharmaceutical research and development.